Search
Novo Nordisk Signs $812 Million Licensing Deal with Deep Apple, a Leading Biotech Company
2025-06-12 /
Read about 0 minute
Author：小编
Novo Nordisk and Deep Apple Therapeutics have inked an $812 million agreement to collaboratively develop therapeutic drugs targeting heart metabolic disorders, including obesity. Leveraging its AI-driven platform, Deep Apple will expedite the drug discovery process through advanced virtual library screening techniques.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
